Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
scPharmaceuticals Inc (SCPH)
NASDAQ:SCPH
SCPH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.08 - $6.54
Previous CloseN/A
Volume61.66K
Average Volume (3M)273.81K
Market Cap
$168.13M
Enterprise Value$173.32M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Mar 19, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.91
Shares Outstanding50,040,134
10 Day Avg. Volume318,656
30 Day Avg. Volume273,813
Standard Deviation0.17
R-Squared0.00107
Alpha0.00221
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.73
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.03
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit17.72
Enterprise Value/Ebitda-2.42
Forecast
1Y Price Target
$16.67Price Target Upside396.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
scPharmaceuticals News
PremiumCompany Announcements
scPharmaceuticals Reports Strong Growth in Q3 2024
---
Bulls Say, Bears Say
Bulls Say
Indication ExpansionPotential indication expansion in chronic kidney disease, if approved, could be a significant positive factor.
Medicare Part D RedesignPositive effects of the Medicare Part D redesign are expected to lower patient copays and beneficially offset higher gross-to-net dynamics via higher volumes.
Salesforce ExpansionThe expanded Furoscix salesforce is expected to have beneficial effects on prescribing and awareness, with approximately 90 total representatives.
Bears Say
Coverage Gap ImpactHigher than expected number of Medicare patients remained in the coverage gap, resulting in higher rebates and fill rates affected by high copays.
Revenue ImpactRevenues for Furoscix in 3Q were impacted by higher gross-to-net from lagging CMS reporting on coverage gap rebates.
Stock Price DeclineShares are trading down ~13% due to the lower than expected revenue which was mostly due to Medicare coverage gap patients being unable or unwilling to fill scripts.
---
Ownership Overview
21.29% Insiders
6.44% Mutual Funds
0.10% Other Institutional Investors
65.76% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SCPH FAQ
What was scPharmaceuticals Inc’s price range in the past 12 months?
scPharmaceuticals Inc lowest stock price was $3.08 and its highest was $6.54 in the past 12 months.
What is scPharmaceuticals Inc’s market cap?
scPharmaceuticals Inc’s market cap is $168.13M.
When is scPharmaceuticals Inc’s upcoming earnings report date?
scPharmaceuticals Inc’s upcoming earnings report date is Mar 19, 2025 which is in 25 days.
How were scPharmaceuticals Inc’s earnings last quarter?
scPharmaceuticals Inc released its earnings results on Nov 13, 2024. The company reported -$0.75 earnings per share for the quarter, missing the consensus estimate of -$0.298 by -$0.452.
Is scPharmaceuticals Inc overvalued?
According to Wall Street analysts scPharmaceuticals Inc’s price is currently Undervalued.
Does scPharmaceuticals Inc pay dividends?
scPharmaceuticals Inc does not currently pay dividends.
What is scPharmaceuticals Inc’s EPS estimate?
scPharmaceuticals Inc’s EPS estimate is -0.38.
How many shares outstanding does scPharmaceuticals Inc have?
scPharmaceuticals Inc has 50,040,134 shares outstanding.
What happened to scPharmaceuticals Inc’s price movement after its last earnings report?
scPharmaceuticals Inc reported an EPS of -$0.75 in its last earnings report, missing expectations of -$0.298. Following the earnings report the stock price went down -14.066%.
Which hedge fund is a major shareholder of scPharmaceuticals Inc?
Currently, no hedge funds are holding shares in SCPH
---
scPharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.67 (396.13% Upside)
$16.67 (396.13% Upside)
Blogger Sentiment
Bullish
SCPH Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 0.1%
Last 30 Days ▼ 0.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.05%
12-Months-Change
Fundamentals
Return on Equity
-200.65%
Trailing 12-Months
Asset Growth
17.88%
Trailing 12-Months
Company Description
scPharmaceuticals Inc
scPharmaceuticals, Inc.engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include furosemide, used as parenteral diuretic in treating heart failure and ceftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.
---
SCPH Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive overall sentiment driven by significant revenue growth, strategic expansions, and successful financing, despite some challenges with higher discounts and increased net loss.Read More>---
SCPH Stock 12 Month Forecast
Average Price Target
$16.67
▲(396.13% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Eagle Pharmaceuticals
―
Ardelyx
―
Xeris Pharmaceuticals
―
Panbela Therapeutics
―
Best Analysts Covering SCPH
1 Year
1 Year Success Rate
6/18 ratings generated profit
1 Year Average Return
-4.24%
reiterated a buy rating 3 months ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -4.24% per trade.
---